Oncogenic long noncoding RNA landscape in breast cancer

Xu, Shouping; Kong, Dejia; Chen, Qianlin; Ping, Yanyan; Pang, Da

doi:10.1186/s12943-017-0696-6

Cited by 202 publications

(212 citation statements)

References 62 publications

Supporting

Mentioning

203

Contrasting

Order By: Relevance

“…Unlike messenger RNA, lncRNA does not translate into protein products, but instead function via regulation of gene transcription, posttranscriptional regulation of proteins, or epigenetic regulation of chromatin. 6 These results suggest targeting lncRNA for breast cancer diagnosis and treatment could be a promising direction. To date, dozens lncRNAs were found to be dysregulated in human breast cancer, including HOTAIR, 3 NKILA, 4 and MALAT1.…”

Section: Introductionmentioning

confidence: 93%

Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF‐κB and p53

Zhang

Jiang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Long noncoding RNA (lncRNA) maternally expressed 3 (MEG3) has been implicated as a tumor suppressor gene in several human cancer types. However, little is known regarding its involvement and potential mechanism in human breast cancer. In this study, we explored the effect of MEG3 on the growth of human breast cancer cell line MDA‐MB‐231 in vitro and in vivo, and sought to elucidate the potential signaling mechanisms. Ectopic overexpression of MEG3 using a lentiviral vector Lv‐MEG3 significantly inhibited breast cancer cell growth in vitro and a cancer xenograft growth in vivo. MEG3 overexpression led to marked increase of apoptosis in breast cancer cells as determined using flow cytometry and fragmented DNA labeling. Moreover, ectopic expression of MEG3 increased the expression of endoplasmic reticulum (ER) stress–related proteins required for unfolded protein response, including glucose‐regulated protein 78 (GRP78), inositol‐requiring enzyme 1 (IRE1), protein kinase RNA (PKR)‐like ER kinase (PERK), and activated transcription factor 6 (ATF6), as well as proapoptotic proteins CCAAT/enhancer binding protein homologous protein (CHOP) and caspase‐3. Finally, MEG3 overexpression markedly increased nuclear factor κB (NF‐κB) expression, NF‐κB translocation to the nucleus, and p53 expression, whereas pharmacological inhibition of NF‐κB completely abolished MEG3‐induced activation of p53. Together, these results suggest that MEG3 inhibits breast cancer growth and induces breast cancer apoptosis, partially via the activation of the ER stress, NF‐κB and p53 pathways, and that NF‐κB signaling is required for MEG3‐induced p53 activation in breast cancer cells. Our results indicate targeting lncRNA MEG3 may represent a novel strategy for breast cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 93%

Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF‐κB and p53

Zhang

Jiang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…12 lncRNA Yaoyao Guan and Adheesh Bhandari equally contributed to this study. 10,11,18 FOXD3 promoter-associated antisense lncRNA, known as linc1623 in mice, interacts with miR-150, restricting its capability to promoting oxidative stress-induced cell growth that leads to lung epithelial cell death. Downregulation of lncRNA GAS5 causes trastuzumab resistance in breast cancer.…”

Section: Foxd3mentioning

confidence: 99%

lncRNA FOXD3‐AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer

Guan

Bhandari

Xia

et al. 2019

Cell Biochemistry & Function

View full text Add to dashboard Cite

For women, breast cancer is the most commonly diagnosed cancer and the leading cause of women deaths due to cancer. In recent years, increasing long noncoding RNA (lncRNA) has been discovered to be related to tumorigenesis, progression, and prognosis. FOXD3-AS1 is a lncRNA and has been identified as a cancer-promoting gene in glioma. By analysing the FOXD3-AS1 expression in The Cancer Genome Atlas (TCGA) database, we found that FOXD3-AS1 has significantly high expression in breast cancer tumour comparing with the normal tissue. And patients with low FOXD3-AS1 expression had greater survival probability, smaller tumour size, and less distant metastasis. This leads us to peep inquisitively biological function of FOXD3-AS1 in breast cancer. Biological assays demonstrated that silenced FOXD3-AS1 impaired cell proliferation and inhibited cell migration and invasion in breast cancer cell lines (BT549, MDA-MB-231). These results suggest that FOXD3-AS1 could play a potential diagnostics or prognostic biomarker for patients with breast cancer. Significance of the study: We demonstrated that lncRNA FOXD3-AS1 has significantly high expression in breast cancer cell lines comparing with the normal tissue. Besides, our findings suggested that lncRNA FOXD3-AS1 could play a potential diagnostics or prognostic biomarker for patients with breast cancer. KEYWORDS FOXD3-AS1, breast cancer, invasion, lncRNA, migration 1 | INTRODUCTION Breast cancer is the first cause of new cancer diagnoses in women, approximately 30% of all new cases. And breast cancer is the second cause of leading cancer deaths; about 14% of all cancer deaths in women, the first cause is lung and bronchus cancer. From 2005 to 2014, breast cancer incidence has a slight increase. Nonwhite women promote the overwhelming majority of the increase (increases 1.7%per year among Asian and 0.3%-0.4% per year among Hispanic and black). 1,2 The higher diagnosing rate is probably because of the development of medical services and perfection of medical insurance. As the development of medical technology, significant advances have been made in the management of breast cancer. 3,4 But the death rate of breast cancer is still high, and patient outcomes still merit attention.As is known, tumorigenesis is related to the environment, living habits, aging, and so on. 5,6 But the molecular mechanisms of breast tumorigenesis still remain unclear. A lot of studies have discovered many oncogenes and tumour suppressor genes, which are acknowledged to be related to the occurrence of breast cancer. [7][8][9] Long noncoding RNAs as a heterogeneous class of noncoding RNAs, which are longer than 200 nucleotides, have been identified to involve in many human diseases, including tumorigenesis. 10,11 A few long noncoding RNAs (lncRNAs) have been identified as oncogenic or suppressor genes and regulate the progress of breast cancer. 12 lncRNA Yaoyao Guan and Adheesh Bhandari equally contributed to this study.

show abstract

“…Previous genome-wide screening studies using lncRNA datasets from GEO and TCGA in lung cancer [55,56], gastric cancer [44] and breast cancer [57,58] also identified cell cycle-related lncRNAs. Several studies reported that dysregulation of specific lncRNAs in HCC cell lines caused cell cycle arrest and induced apoptosis, and affected the prognosis of HCC [59,60].…”

Section: Discussionmentioning

confidence: 90%

Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma

Liao

Yang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The aim of the current study was to identify potential prognostic long non-coding RNA (lncRNA) biomarkers for predicting survival in patients with hepatocellular carcinoma (HCC) using The Cancer Genome Atlas (TCGA) dataset and bioinformatics analysis. Methods: RNA sequencing and clinical data of HCC patients from TCGA were used for prognostic association assessment by univariate Cox analysis. A prognostic signature was built using stepwise multivariable Cox analysis, and a comprehensive analysis was performed to evaluate its prognostic value. The prognostic signature was further evaluated by functional assessment and bioinformatics analysis. Results: Thirteen differentially expressed lncRNAs (DELs) were identified and used to construct a single prognostic signature. Patients with high risk scores showed a significantly increased risk of death (adjusted P < 0.0001, adjusted hazard ratio = 3.522, 95% confidence interval = 2.307–5.376). In the time-dependent receiver operating characteristic analysis, the prognostic signature performed well for HCC survival prediction with an area under curve of 0.809, 0.782 and 0.79 for 1-, 3- and 5-year survival, respectively. Comprehensive survival analysis of the 13-DEL prognostic signature suggested that it serves as an independent factor in HCC, showing a better performance for prognosis prediction than traditional clinical indicators. Functional assessment and bioinformatics analysis suggested that the prognostic signature was associated with the cell cycle and peroxisome proliferator-activated receptor signaling pathway. Conclusions: The novel lncRNA expression signature identified in the present study may be a potential biomarker for predicting the prognosis of HCC patients.

show abstract

Oncogenic long noncoding RNA landscape in breast cancer

Cited by 202 publications

References 62 publications

Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF‐κB and p53

Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF‐κB and p53

lncRNA FOXD3‐AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer

Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Survival in Patients with Hepatocellular Carcinoma

Contact Info

Product

Resources

About